Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

Journal of Clinical Oncology

Volumn 27, Issue 33, 2009, Pages 5601-5606

  Matulonis, Ursula A ^a   Berlin, Suzanne ^a   Ivy, Percy ^a   Tyburski, Karin ^a   Krasner, Carolyn ^a   Zarwan, Corrine ^a   Berkenblit, Anna ^a   Campos, Susana ^a   Horowitz, Neil ^a   Cannistra, Stephen A ^a   Lee, Hang ^a   Lee, Julie ^a   Roche, Maria ^a   Hill, Margaret ^a   Whalen, Christin ^a   Sullivan, Laura ^a   Tran, Chau ^a   Humphreys, Benjamin D ^a   Penson, Richard T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; STEM CELL FACTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; 4 ((4 FLUORO 2 METHYL 1H INDOL 5 YL)OXY) 6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINAZOLINE; 4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-(3-(PYRROLIDIN-1-YL)PROPOXY)QUINAZOLINE; QUINAZOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRY SKIN; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; HYPOTHYROIDISM; INTESTINE FISTULA; INTESTINE PERFORATION; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RECTUM HEMORRHAGE; RECURRENT CANCER; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UTERINE TUBE CARCINOMA; VOICE CHANGE; VOMITING; WEIGHT REDUCTION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEOPLASM; ORAL DRUG ADMINISTRATION; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE; UTERINE TUBE TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 73949123481     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.2777     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics 2008. CA Cancer J Clin 58:71-96, 2008
2. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al: Long term survival in ovarian cancer: Mature data from The Netherlands Joint Study Group for Ovarian cancer. Eur J Cancer 27: 1367-1372, 1991
3. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
4. Bookman MA, McGuire WP, Kilpatrick D, et al: Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 14:1895-1902, 1996
5. Cannistra S, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007
6. Burger RA, Sill MV, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:5165-5171, 2007
7. Wedge SR, Kendrew J, Hennequin, et al: Cediranib: A highly potent orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400, 2005
8. Heckman CA, Holopainen T, Wirzenius M, et al: The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 68:4754-4762, 2008
9. Kerbel RS: Tumor angiogenesis. N Engl J Med 358:2039-2049, 2008
10. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
11. Kowanetz M, Ferrara N: Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res 12:5018-5022, 2006
12. He Y, Kozaki K, Karpanen T, et al: Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94: 819-825, 2002
13. Drevs J, Siegert P, Medinger M, et al: Phase I clinical study of cediranib, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:3045-3054, 2007
14. Batchelor T, Sorenson AG, Ancukiewicz M, et al: Phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 25:75s, 2007 (suppl 18S; abstr 2001)
15. Karakunnel JJ, Gulley JL, Arlen PM, et al: Phase II trial of AZD2171 in docetaxel-resistant, castrate-resistant prostate cancer (CRPC). J Clin Oncol 26:283s, 2008 (suppl; abstr 5136)
16. Sridhar SS, Mackenzie MJ, Hotte SJ, et al: Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC): A phase II trial of the PMH Consortium. J Clin Oncol 26:261s, 2008 (suppl; abstr 5047)
17. Ramalingam SS, Mack PC, Vokes EE, et al: Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097). J Clin Oncol 26:443s, 2008 (suppl; abstr 8078)
18. Hirte HW, Vidal L, Fleming GF, et al: A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J Clin Oncol 26:298s, 2008 (suppl; abstr 5521)
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
20. Vergote I, Rustin GJS, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 92:1534-1535, 2000
21. Rustin G, Quinn, Thigpen T, et al: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96:487-488, 2004
22. Scartozzi M, Galizia E, Chiorrini S, et al: Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20:227-230, 2009
23. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572, 2009
24. Verheul HMW, Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475-485, 2007
25. Vergote I, Trope CG, Amant F, et al: EORTC-GCG/NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer. Presented at the 12th Biennial Meeting of the International Gynecologic Cancer Society, Bangkok, Thailand, October 25-28, 2008
26. Laurie SA, Gauthier I, Arnold A, et al: Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small lung cancer: The National Cancer Institute of Canada Clinical Trials group. J Clin Oncol 26:1871-1878, 2008